Table 2 Clinical characteristics of PLHIV on second-line antiretroviral therapy in the Eastern Amhara region, Northeast Ethiopia, December 2020–February 2021 (n = 714)
Clinical characteristics | Total (714) N (%) | Depression (198) N (%) |
|---|---|---|
BMI | Â | Â |
 >  = 18.5 kg/m2 | 545 (76.3) | 146 (26.8) |
 < 18.5 kg/m2 | 169 (23.7) | 52 (30.8) |
Functional status | Â | Â |
 Workable | 608 (85.2) | 134 (22.0) |
 Not workable | 106 (14.8) | 64 (60.4) |
WHO clinical stage | Â | Â |
 I and II | 685 (95.9) | 179 (26.1) |
 III and IV | 29 (4.1) | 19 (65.5) |
Last HIV viral load measurement | Â | Â |
 High viremia | 540 (75.6) | 110 (20.4) |
 Low viremia | 174 (24.4) | 88 (50.6) |
Last CD4 cells measurement | Â | Â |
 <  = 450 cell/mm3 | 603 (84.5) | 174 (28.9) |
 > 450 cell/mm3 | 111 (15.5) | 24 (21.6) |
Medication adherence | Â | Â |
 Optimal adherence | 679 (95.1) | 174 (25.6) |
 Not optimal adherence | 35 (4.9) | 24 (68.6) |
Comorbidity status | Â | Â |
 No | 651 (91.2) | 156 (24.0) |
 Yes | 63 (8.8) | 42 (66.7) |
Second-line ART | Â | Â |
 TDF-3TC-ATV/r | 361 (50.6) | 91 (25.2) |
 AZT-3TC-ATV/r | 338 (47.3) | 100 (29.6) |
 TDF-3TC-LPV/r | 11 (1.5) | 6 (54.5) |
 AZT-3TC-LPV/r | 4 (0.6) | 1 (25) |